Non-chemotherapy metastatic breast cancer solution now available in Malaysia
INNOVATIVE healthcare solutions provider Novartis has announced results from the RIGHT Choice phase II trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive for